Biovet JSCLTS:0III ROE % is 15.87% as of Dec. 2016, which is 53% above its 10-year median of 10.35. The stock has 1 warning sign investors should review.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Biovet JSC's annualized net income for the quarter that ended in Dec. 2016 was лв20.58 Mil. Biovet JSC's average Total Stockholders Equity over the quarter that ended in Dec. 2016 was лв129.68 Mil. Therefore, Biovet JSC's annualized ROE % for the quarter that ended in Dec. 2016 was 15.87%.
The historical rank and industry rank for Biovet JSC's ROE % or its related term are showing as below:
LTS:0III'
s ROE % Range Over the Past 10 Years
Min: 3 Med: 10.35 Max: 16.94
Current: 13.83
During the past 8 years, Biovet JSC's highest ROE % was 16.94%. The lowest was 3.00%. And the median was 10.35%.
LTS:0III's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 5.865
vs LTS:0III: 13.83
Biovet JSC (LTS:0III) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2016) net income data. The Revenue data used here is four times the quarterly (Dec. 2016) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Biovet JSC ROE % Related Terms
Biovet JSC ROE % Historical Data
* Premium members only.
The historical data trend for Biovet JSC's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biovet JSC's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biovet JSC ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biovet JSC's ROE % distribution charts can be found below:
* The bar in red indicates where Biovet JSC's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2016) net income data.
ROE % is displayed in the 30-year financial page.
Biovet JSC (LTS:0III) has a ROE % of 15.87% as of Dec. 2016. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Biovet JSC and its competitors. This is 53% above median its historical median of 10.35. Over the past decade, Biovet JSC's ROE % has ranged from 3.00 to 16.94.
Is Biovet JSC's ROE % too high?
Biovet JSC's current ROE % of 15.87% is 53% above median its 10-year median of 10.35. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 16.94. The Drug Manufacturers industry median ROE % is 5.87. Biovet JSC's value of 15.87% is 170.6% above this industry median.
How does Biovet JSC's ROE % compare to ADMP and AGRX?
Biovet JSC's ROE % of 15.87% can be compared against companies in the Drug Manufacturers industry. The industry median ROE % is 5.87. Biovet JSC's value of 15.87% is 170.6% above this benchmark. Historically, Biovet JSC's own ROE % has ranged from 3.00 to 16.94 over the past decade. While the company's 10-year median is 10.35 vs. the industry median of 5.87, Biovet JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biovet JSC's current ROE % of 15.87% is 170.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Biovet JSC and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biovet JSC's current ROE % is 15.87%, which is 53% above median its own 10-year median of 10.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biovet JSC stock overvalued right now?
Biovet JSC (LTS:0III) has a current ROE % of 15.87%. The current ROE % is 15.87%, which is 53% above median its 10-year median of 10.35 and 170.6% above the Drug Manufacturers industry median of 5.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Biovet JSC (LTS:0III), the current ROE % is 15.87% as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biovet JSC manufactures & markets medicated and nutritional feed additives, enzymes, bulk active substances & pharmaceuticals for animal productivity & health. It offers intermediates, active ingredients and medicines for human pharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0III has been successfully added to your 